Jaguar Health Hauptforum Forum: Community User: MaLiMo

https://jaguarhealth.gcs-web.com/email-alerts

ich bin erstmal raus was die news betreffen. falls ihr auf dem laufenden bleiben wollt, hier könnt ihr euch anmelden

https://jaguarhealth.gcs-web.com/news-releases/news-release-details/jaguar-health-secures-new-patent-crofelemer-short-bowel-syndrome

Und ⛷️ geht's,zum nächsten RS..🤦🤦

Keiner glaubt das JH in den nächsten 10 Jahren ein Produkt auf den Markt bringt, was der Menschheit einen Mehrwert bringt.

Die Testreihen mit so „bahnbrechenden“ Ergebnissen lassen den Kurs sinken 🤮

⛷️🚮🚮

https://jaguarhealth.gcs-web.com/news-releases/news-release-details/jaguar-health-reports-third-quarter-2025-financials-net-q3-2025

https://jaguarhealth.gcs-web.com/node/15601/html

https://jaguarhealth.gcs-web.com/node/15596/html

Die Aktionäre haben Lisa Conte ne goldene Klobrille finanziert.Sie ist die Split Queen...

unglaublich das dieses Unternehmen noch existiert, der RS König der US Börse, von mir keine Kaufempfehlung, würden die heisse Luft in Ballons verkaufen, wäre die Marketcap. höher 🤭

https://jaguarhealth.gcs-web.com/node/15551/html

They announced that the maturity date of some convertible promissory notes (≥ US$2.57 million) from their March 2025 bridge financing has been extended from 30 June 2025 to 30 January 2026. jaguarhealth.gcs-web.com • The extension provides short-term financial flexibility and avoids an immediate liquidity crunch. • While not a "business triumph", it is a positive step in managing financial risk. 3. They received notice of a US$250,000 grant from the U.S. Food and Drug Administration (FDA) to fund a confirmatory trial to support approval of their veterinary product (Canalevia® for dogs with chemotherapy-induced diarrhea).

Das sagt Chat GPT Positive developments 1. The company announced proof-of-concept results for its drug crofelemer in pediatric intestinal failure patients: it reduced the need for total parenteral nutrition (TPN) by up to ~27% in one microvillus-inclusion-disease (MVID) patient and ~12.5 % in an SBS-IF (short bowel syndrome with intestinal failure) patient. GuruFocus +1 • This is a meaningful result given the seriousness of these orphan conditions. • It supports the company's rare-disease development strategy. • The company says 2025 is a "year of catalysts" for crofelemer in both rare-disease intestinal failure and cancer therapy-related diarrhea.